Aditya Bardia
Led ASCENT, the trial that made sacituzumab govitecan the first ADC for triple-negative breast cancer, and the EMERALD trial of elacestrant.
Overview
Aditya Bardia was principal investigator of ASCENT, which showed sacituzumab govitecan nearly doubles survival in pretreated metastatic TNBC, and of EMERALD, which won elacestrant the first oral SERD approval for ESR1-mutant disease. He is a lead investigator on the TROPION-Breast programme and ctDNA-guided studies. His work has defined the TROP2 ADC class in breast cancer.
For hormone-receptor-positive metastatic breast cancer that has already had chemotherapy, Dato-DXd controls the disease for longer with fewer severe side effects than chemotherapy, but does not help patients live longer, so it is not a standard option here. The result is a reminder that progression-free survival is a surrogate; regulators and clinicians should wait for survival data before adopting an ADC in a setting where later therapies are effective.
Sacituzumab govitecan is a standard second-line or later treatment for metastatic triple-negative breast cancer, roughly doubling survival compared with the chemotherapies it was tested against. Patients should expect neutropenia and diarrhoea, which are manageable with growth factor support and loperamide. Trials are now testing it earlier, in first-line combinations with pembrolizumab and after surgery for residual disease.
Pages like this
not linked directly; found by shared links- PersonStephen Johnston
Shares Estrogen receptor (ERα), Endocrine therapy (SERMs, AIs, SERDs), HR-positive / HER2-negative breast cancer and the tags breast, trialist.
- PersonGabriel N. Hortobagyi
Shares HR-positive / HER2-negative breast cancer and the tags breast, trialist.
- PersonShanu Modi
Shares Antibody-drug conjugate (ADC), Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags breast, adc.
- PersonRichard S. Finn
Shares UCLA Jonsson Comprehensive Cancer Center, HR-positive / HER2-negative breast cancer and the tags breast, trialist.
- PersonSara M. Tolaney
Shares TROPION-Breast01, ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer, Sacituzumab govitecan, Datopotamab deruxtecan.
- PersonIan E. Krop
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
- PersonCristina Saura
Shares Antibody-drug conjugate (ADC) and the tags breast, adc.
- PersonFrançois-Clément Bidard
Shares EMERALD, Elacestrant, Estrogen receptor (ERα), Liquid biopsy (ctDNA).